Journal of Nephrology & Therapeutics

Jan Galle

Publications

• Research Article
  Continuous Erythropoietin Receptor Activator (C.E.R.A.) Treatment of Renal Anemia in Patients with Chronic Kidney Disease: A Two-Year Observational Study
  Author(s): Jan GalleJan Galle
  
  Objective: To evaluate once-monthly continuous erythropoiesis receptor activator (C.E.R.A.) in patients with chronic kidney disease (CKD) for two years under standard conditions. Methods: In a non-interventional study, C.E.R.A. was administered according to local practice in patients with dialysis dependent or non-dialysis dependent CKD. Results: 206 patients were evaluable to month 24. In the dialysis dependent and non-dialysis dependent patients who had received ESA therapy prior to study entry, Hb remained stable from baseline to the end of the study: mean (SD) change was -0.3 (1.5) g/dL (n=148) and 0.3 (1.6) g/dL (n=33), respectively. The mean (SD) dose of C.E.R.A. was 114 (78) μg in dialysis dependent patients and 97 (71) &mu.. Read More»
  DOI: 10.4172/2161-0959.1000228

  Abstract PDF